CMap Candidates
CMap (Connectivity Map) candidates are extracted from CLUE (CMap and LINCS Unified Environment), with detailed information, e.g., perturbagen time and dose, compound structure, targets, SMILES, mechanism of action. Two publicly available gene expression profiles of NAFLD are used to calculate individual connectivity scores and corresponding statistical significances for these candidates.
stats1
stats2
34330 records.
CMap ID | Pert ID | Compound Name | Targets | MoA | Compound Aliases | |
---|---|---|---|---|---|---|
C17204 | BRD-K46393778 | BRD-K46393778 | -- | -- | -- | Details |
C17205 | BRD-K46396728 | BRD-K46396728 | -- | -- | -- | Details |
C17206 | BRD-K46400317 | BRD-K46400317 | -- | -- | -- | Details |
C17207 | BRD-K46401069 | BRD-K46401069 | -- | -- | -- | Details |
C17208 | BRD-K46407773 | BRD-K46407773 | -- | -- | -- | Details |
C17209 | BRD-K46412655 | BRD-K46412655 | -- | -- | -- | Details |
C17210 | BRD-K46413323 | BRD-K46413323 | -- | -- | -- | Details |
C17211 | BRD-K46416377 | BRD-K46416377 | -- | -- | -- | Details |
C17212 | BRD-K46419649 | U-0126 | MAP2K1; MAP2K2 | MEK inhibitor | -- | Details |
C17213 | BRD-K46419847 | BRD-K46419847 | -- | -- | -- | Details |
C17214 | BRD-K46424862 | hymecromone | MAOA; MAOB | Monoamine oxidase inhibitor | -- | Details |
C17215 | BRD-K46428124 | BRD-K46428124 | -- | -- | -- | Details |
C17216 | BRD-K46428287 | BRD-K46428287 | -- | -- | -- | Details |
C17217 | BRD-K46429791 | BRD-K46429791 | -- | -- | -- | Details |
C17218 | BRD-K46435528 | trichloroethylene | -- | -- | -- | Details |
C17219 | BRD-K46435977 | valaciclovir | -- | -- | -- | Details |
C17220 | BRD-K46439376 | BRD-K46439376 | -- | -- | -- | Details |
C17221 | BRD-K46441700 | GR-55562 | HTR1B | Serotonin receptor antagonist | -- | Details |
C17222 | BRD-K46445327 | BRD-K46445327 | -- | -- | -- | Details |
C17223 | BRD-K46445956 | BRD-K46445956 | -- | -- | -- | Details |
C17224 | BRD-K46446437 | BRD-K46446437 | -- | -- | -- | Details |
C17225 | BRD-K46447740 | BRD-K46447740 | -- | -- | -- | Details |
C17226 | BRD-K46448313 | BRD-K46448313 | -- | -- | -- | Details |
C17227 | BRD-K46450665 | BRD-K46450665 | -- | -- | -- | Details |
C17228 | BRD-K46458719 | BRD-K46458719 | -- | -- | -- | Details |
C17229 | BRD-K46469693 | SCH-442416 | ADORA1; ADORA2A | Adenosine receptor antagonist | -- | Details |
C17230 | BRD-K46473681 | BRD-K46473681 | -- | -- | -- | Details |
C17231 | BRD-K46476470 | BRD-K46476470 | -- | -- | -- | Details |
C17232 | BRD-K46476822 | BRD-K46476822 | -- | -- | -- | Details |
C17233 | BRD-K46477974 | BRD-K46477974 | -- | -- | -- | Details |
C17234 | BRD-K46489288 | BRD-K46489288 | -- | -- | -- | Details |
C17235 | BRD-K46493214 | saccharin | -- | -- | -- | Details |
C17236 | BRD-K46494135 | BRD-K46494135 | -- | -- | -- | Details |
C17237 | BRD-K46496627 | BRD-K46496627 | -- | -- | -- | Details |
C17238 | BRD-K46498981 | BRD-K46498981 | -- | -- | -- | Details |
C17239 | BRD-K46499837 | BRD-K46499837 | -- | -- | -- | Details |
C17240 | BRD-K46503544 | etoposide | TOP2A; TOP2B | Topoisomerase inhibitor | -- | Details |
C17241 | BRD-K46504268 | BRD-K46504268 | -- | -- | -- | Details |
C17242 | BRD-K46505016 | BRD-K46505016 | -- | -- | -- | Details |
C17243 | BRD-K46512534 | BRD-K46512534 | -- | -- | -- | Details |
C17244 | BRD-K46512834 | BRD-K46512834 | -- | -- | -- | Details |
C17245 | BRD-K46522835 | BRD-K46522835 | -- | -- | -- | Details |
C17246 | BRD-K46523383 | pramocaine | -- | -- | -- | Details |
C17247 | BRD-K46525610 | BRD-K46525610 | -- | -- | -- | Details |
C17248 | BRD-K46526566 | BRD-K46526566 | -- | -- | -- | Details |
C17249 | BRD-K46531780 | methyl-benzethonium | -- | -- | -- | Details |
C17250 | BRD-K46532897 | BRD-K46532897 | -- | -- | -- | Details |
C17251 | BRD-K46532981 | BRD-K46532981 | -- | -- | -- | Details |
C17252 | BRD-K46533463 | BRD-K46533463 | -- | -- | -- | Details |
C17253 | BRD-K46544760 | BRD-K46544760 | -- | -- | -- | Details |
C17254 | BRD-K46549154 | BRD-K46549154 | -- | -- | -- | Details |
C17255 | BRD-K46555627 | BRD-K46555627 | -- | -- | -- | Details |
C17256 | BRD-K46555875 | BRD-K46555875 | -- | -- | -- | Details |
C17257 | BRD-K46556387 | BRD-K46556387 | -- | -- | -- | Details |
C17258 | BRD-K46556543 | potassium-canrenoate | NR3C2 | Mineralocorticoid receptor antagonist | -- | Details |
C17259 | BRD-K46558254 | BRD-K46558254 | -- | -- | -- | Details |
C17260 | BRD-K46560430 | BRD-K46560430 | -- | -- | -- | Details |
C17261 | BRD-K46561246 | BRD-K46561246 | -- | -- | -- | Details |
C17262 | BRD-K46561506 | BRD-K46561506 | -- | -- | -- | Details |
C17263 | BRD-K46562045 | BRD-K46562045 | -- | -- | -- | Details |
C17264 | BRD-K46562329 | BRD-K46562329 | -- | -- | -- | Details |
C17265 | BRD-K46574442 | BRD-K46574442 | -- | -- | -- | Details |
C17266 | BRD-K46575753 | BRD-K46575753 | -- | -- | -- | Details |
C17267 | BRD-K46580984 | phenserine | APP; ACHE; BCHE | Beta amyloid inhibitor; Acetylcholinesterase inhibitor | -- | Details |
C17268 | BRD-K46585355 | acetylsalicylsalicylic-acid | -- | -- | -- | Details |
C17269 | BRD-K46587586 | SA-1456508 | -- | -- | -- | Details |
C17270 | BRD-K46588240 | BRD-K46588240 | -- | -- | -- | Details |
C17271 | BRD-K46592487 | BRD-K46592487 | -- | -- | -- | Details |
C17272 | BRD-K46593635 | BRD-K46593635 | -- | -- | -- | Details |
C17273 | BRD-K46594703 | BRD-K46594703 | -- | -- | -- | Details |
C17274 | BRD-K46597784 | BRD-K46597784 | -- | -- | -- | Details |
C17275 | BRD-K46599299 | BRD-K46599299 | -- | -- | -- | Details |
C17276 | BRD-K46599443 | BRD-K46599443 | -- | -- | -- | Details |
C17277 | BRD-K46603043 | BRD-K46603043 | -- | -- | -- | Details |
C17278 | BRD-K46604138 | dapagliflozin | SLC5A2 | Sodium/glucose cotransporter inhibitor | -- | Details |
C17279 | BRD-K46604793 | BRD-K46604793 | -- | -- | -- | Details |
C17280 | BRD-K46607226 | BRD-K46607226 | -- | -- | -- | Details |
C17281 | BRD-K46609723 | BRD-K46609723 | -- | -- | -- | Details |
C17282 | BRD-K46610687 | BRD-K46610687 | -- | -- | -- | Details |
C17283 | BRD-K46619710 | BRD-K46619710 | -- | -- | -- | Details |
C17284 | BRD-K46620987 | BRD-K46620987 | -- | -- | -- | Details |
C17285 | BRD-K46622484 | BRD-K46622484 | -- | -- | -- | Details |
C17286 | BRD-K46623934 | BRD-K46623934 | -- | -- | -- | Details |
C17287 | BRD-K46625537 | BRD-K46625537 | -- | -- | -- | Details |
C17288 | BRD-K46625679 | MW-STK33-97 | -- | -- | -- | Details |
C17289 | BRD-K46629170 | BRD-K46629170 | -- | -- | -- | Details |
C17290 | BRD-K46639367 | BRD-K46639367 | -- | -- | -- | Details |
C17291 | BRD-K46641047 | BRD-K46641047 | -- | -- | -- | Details |
C17292 | BRD-K46643133 | BRD-K46643133 | -- | -- | -- | Details |
C17293 | BRD-K46645809 | BRD-K46645809 | -- | -- | -- | Details |
C17294 | BRD-K46652470 | nizatidine | HRH2 | Histamine receptor antagonist | -- | Details |
C17295 | BRD-K46653995 | BRD-K46653995 | -- | -- | -- | Details |
C17296 | BRD-K46654563 | zofenopril-calcium | ACE | Angiotensin converting enzyme inhibitor | -- | Details |
C17297 | BRD-K46655163 | BRD-K46655163 | -- | -- | -- | Details |
C17298 | BRD-K46658587 | BRD-K46658587 | -- | -- | -- | Details |
C17299 | BRD-K46661156 | BRD-K46661156 | -- | -- | -- | Details |
C17300 | BRD-K46663433 | BRD-K46663433 | -- | -- | -- | Details |
C17301 | BRD-K46664882 | BRD-K46664882 | -- | -- | -- | Details |
C17302 | BRD-K46666779 | BRD-K46666779 | -- | -- | -- | Details |
C17303 | BRD-K46670060 | BRD-K46670060 | -- | -- | -- | Details |